Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

Strong investor syndicate backs clinical-stage Hepatitis B program while advancing pioneering gene-tuning platform DURHAM, N.C. & SEATTLE–(BUSINESS WIRE)–Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates, Yosemite, Regeneron Ventures and Hevolution Foundation. “It is deeply gratifying to have seen this platform and company evolve […]